Lonza has entered an agreement with Pharmacyclics to provide commercial and clinical production of Pharmacyclics’ oral oncology drug, IMBRUVICA (Ibrutinib). Lonza previously provided development services and clinical manufacture, which was used for Pharmacyclics’ NDA submission and approval. Lonza will continue to support the production of commercial and clinical material under a long-term agreement.   Pharmacyclics received FDA approval of IMBRUVICA in November for the treatment of patients wit...